Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Government Shutdown Stymies U.S. Research Efforts
New Rochelle, NY, October 16, 2013—Over 73% of U.S. scientists responding to a Genetic Engineering & Biotechnology News (GEN) poll say that the current government shutdown is impacting their ability to carry out their research projects.
According to the GEN survey question, “Has the government shutdown affected your research projects?,” 39.7% replied significantly; 21.8% said moderately; 12% responded slightly; and 26.5% were not affected at all.
The results of the GEN survey echo the thoughts of officials at the American Society for Cell Biology, the Ludwig Institute for Cancer Research, and the University of California, San Diego. Their consensus was that American political shortsightedness has huge ramifications for the life science community right now and will continue to do so for the future. (You can read the story here.)
“Not only do these kinds of government actions hurt U.S. competitiveness on the global biotechnology stage but, more importantly, it hinders scientists’ abilities to come up with life-saving drugs and effective therapies for a host of serious diseases,” says John Sterling, editor in chief of GEN.